Active Biotech's nomination committee appointed
In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board.
If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.
Based on the above, the Nomination Committee is composed with participants representing the largest shareholders in Active Biotech as of September 30, 2021, and consists of:
Michael Shalmi, chairman
Mats Arnhög, MGA Holding
Per Colleen, 4:e AP Fonden
Peter Thelin
For the 2022 Annual General Meeting, the Nomination Committee shall prepare and submit proposals regarding the Chairman of the AGM, the number of Board members, a Chairman and Board members elected by the AGM, the fees and other renumerations to Board members and Board committee´s, number of auditors, the auditor, fees to auditors and election of a Nomination Committee.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information was submitted for publication, through the agency of the contact person set out above, at 13.00pm CET on December 10, 2021.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab25.4.2024 04:11:25 CEST | Press release
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (“NPC”), and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combina
Net Income of R$ 55.3 mm in 1Q24, a 90.1% Increase YOY and Leases EBITDA Margin of 72.1%25.4.2024 02:58:18 CEST | Press release
On track to deliver 2024 Record Production of 500,000 sqm of GLA BELO HORIZONTE, Brazil, April 24, 2024 (GLOBE NEWSWIRE) -- Log Commercial Properties (B3: LOGG3), a leading developer of greenfield assets and lessor of Class A logistics warehouses in Brazil, is pleased to announce its financial results for the first quarter. 1Q24 Operational Highlights: Deliveries totaling 57,000 sqm of GLA were completed with a 100% pre-lease rateMilestone of 2.0 million sqm of GLA historically delivered by the CompanyGross absorption of 134,000 sqm of GLAStabilized vacancy of 0.91%,Same Client Rent of 1,9%, above inflation for the 7th consecutive quarter 1Q24 Financial Highlights: Strong EBITDA of R$ 74.0 million in 1Q24, with a growth of 36.4%EBITDA from leases of R$ 38.8 million and a margin of 72.1% in 1Q24Asset recycling of R$ 1.7 billion in the last 12 monthsAdjusted net debt reduction of 37.4%, totaling R$ 744.3 million in 1Q24Adjusted leverage of 0.8x considering the asset sales in April Manage
Elavon and FreedomPay to transform payments for hospitality and retail in Europe25.4.2024 01:01:00 CEST | Press release
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Elavon, a leading global payments provider, today announces its expanded collaboration in Europe with FreedomPay, a global leader in Next Level Commerce™ technologies. The partnership aims to deliver cutting-edge integrated commerce solutions and omni-channel payments technology to large enterprise merchants across Retail and Hospitality. The agreement pairs Elavon acquiring with FreedomPay commerce technologies to benefit Elavon merchants across Europe, empowering businesses with enhanced payment flexibility and optionality, data security, and a seamlessly integrated payments technology across both physical and ecommerce channels. “Elavon and FreedomPay have an enviable track record in Europe of helping hospitality and retail merchants grow their operations and better meet their customers’ needs,” said Hemlata Narasimhan, President of Elavon in Europe. “We’re pleased to extend our relationship with FreedomPay to continue to offer the first-cl
Ensurge Micropower ASA - Grant of Incentive Subscription Rights24.4.2024 23:30:00 CEST | Press release
The Board of Directors of Ensurge Micropower ASA (the "Company") resolved on 24 April 2024 to issue a total of 202,200 incentive subscription rights to employees in the Ensurge group. The grants were made under the Company's 2023 incentive subscription rights plan, as resolved at the Annual General Meeting on 24 May 2023, and amended on the Extraordinary General Meeting held on 10 November 2023. The exercise price of the subscription rights is calculated to NOK 1.2640 per share. The subscription rights expire on 24 May 2028. The subscription rights follow the terms and conditions of the 2023 subscription rights incentive plan. Following the grant there are 46,057,881 incentive subscription rights issued and outstanding in the Company. For more information, please contact: Lars Eikeland, Chief Executive Officer E- mail: lars.eikeland@ensurge.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bombardier Unveils Bold New Brand Identity Worldwide as Company Soars Toward an Ambitious Future24.4.2024 23:12:07 CEST | Press release
A new logo celebrates the company’s successful shift toward pure-play business aviation. The symbol itself, the Bombardier Mach, features the silhouette of an aircraft breaking the sound barrier, while the strokes of wind over a wing reference the company’s heritageThe employee value proposition “where heart meets mastery” focuses on Bombardier’s talented people, celebrating the workforce’s renowned passion, its incredible craftsmanship and profound technological expertise MONTRÉAL, April 24, 2024 (GLOBE NEWSWIRE) -- Bombardier, the worldwide leader in business aviation, today unveiled a new brand identity anchored by the evolution of the company’s logo. As Bombardier successfully moves forward as a company with a sole focus on designing, building and servicing the world’s best business jets, the new brand identity will reinforce and propel the company’s unique approach to its customers and stakeholders—putting people at the centre and instilling a one-of-a-kind sense of family. Bombar